BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32361007)

  • 41. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.
    Scarfone C; Lavely WC; Cmelak AJ; Delbeke D; Martin WH; Billheimer D; Hallahan DE
    J Nucl Med; 2004 Apr; 45(4):543-52. PubMed ID: 15073248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early metabolic 18F-FDG PET/CT response of locally advanced squamous-cell carcinoma of head and neck to induction chemotherapy: A prospective pilot study.
    Nicolau UR; de Jesus VHF; Lima ENP; Alves MS; de Oliveira TB; Andrade LB; Silva VS; Bes PC; de Paiva TF; Calsavara VF; Guimarães APG; Cezana L; Barbosa PNVP; Porto GCLM; Pellizzon ACA; de Carvalho GB; Kowalski LP
    PLoS One; 2018; 13(8):e0200823. PubMed ID: 30114190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Deep Learning Model for Predicting Xerostomia Due to Radiation Therapy for Head and Neck Squamous Cell Carcinoma in the RTOG 0522 Clinical Trial.
    Men K; Geng H; Zhong H; Fan Y; Lin A; Xiao Y
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):440-447. PubMed ID: 31201897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma.
    Périé S; Hugentobler A; Susini B; Balogova S; Grahek D; Kerrou K; Montravers F; Chater PE; St Guily JL; Talbot JN
    Otolaryngol Head Neck Surg; 2007 Oct; 137(4):647-53. PubMed ID: 17903585
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
    Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma.
    Wang D; Schultz CJ; Jursinic PA; Bialkowski M; Zhu XR; Brown WD; Rand SD; Michel MA; Campbell BH; Wong S; Li XA; Wilson JF
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):143-51. PubMed ID: 16618577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy.
    Solberg TD; Agazaryan N; Goss BW; Dahlbom M; Lee SP
    J Neurosurg; 2004 Nov; 101 Suppl 3():381-9. PubMed ID: 15537193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
    Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
    Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria.
    Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
    Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PET/CT: Radiation Therapy Planning in Head and Neck Cancer.
    Eraj S; Sher DJ
    PET Clin; 2022 Apr; 17(2):297-305. PubMed ID: 35256302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
    Schouten CS; Hakim S; Boellaard R; Bloemena E; Doornaert PA; Witte BI; Braakhuis BJ; Brakenhoff RH; Leemans CR; Hoekstra OS; de Bree R
    Head Neck; 2016 Apr; 38(4):529-35. PubMed ID: 25352335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis, Staging, Radiation Treatment Response Assessment, and Outcome Prognostication of Head and Neck Cancers Using PET Imaging: A Systematic Review.
    Hohenstein NA; Chan JW; Wu SY; Tahir P; Yom SS
    PET Clin; 2020 Jan; 15(1):65-75. PubMed ID: 31735303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer.
    Vempati P; Halthore AN; Teckie S; Rana Z; Gogineni E; Antone J; Zhang H; Marrero M; Beadle K; Frank DK; Aziz M; Paul D; Ghaly M
    Radiat Oncol; 2020 Dec; 15(1):278. PubMed ID: 33308265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma.
    Wangaryattawanich P; Branstetter BF; Hughes M; Clump DA; Heron DE; Rath TJ
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1884-1888. PubMed ID: 30166429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intensity modulated arc therapy implementation in a three phase adaptive (18)F-FDG-PET voxel intensity-based planning strategy for head-and-neck cancer.
    Berwouts D; Olteanu LA; Speleers B; Duprez F; Madani I; Vercauteren T; De Neve W; De Gersem W
    Radiat Oncol; 2016 Apr; 11():52. PubMed ID: 27039294
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Pedraza S; Ruiz-Alonso A; Hernández-Martínez AC; Cabello E; Lora D; Pérez-Regadera JF
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(3):154-159. PubMed ID: 30655026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.